Last reviewed · How we verify
Cozaar® plus pro tab
Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.
Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Reduction of cardiovascular risk in hypertensive patients.
At a glance
| Generic name | Cozaar® plus pro tab |
|---|---|
| Also known as | Losartan 100mg/ HCTZ 12.5mg |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Angiotensin II receptor antagonist (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral resistance, and decreased blood pressure. The 'pro tab' formulation likely refers to a combination or enhanced delivery form marketed by Hanmi Pharmaceutical.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Reduction of cardiovascular risk in hypertensive patients
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Key clinical trials
- LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED) (PHASE4)
- The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cozaar® plus pro tab CI brief — competitive landscape report
- Cozaar® plus pro tab updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI